Xeris Biopharma Q2 revenue $48.1M (+26% YoY); raises FY revenue guidance to $190-200M; appoints John Shannon CEO

Xeris Biopharma Holdings, Inc.

2024-Q2 EPS reported -$0.24 revenue$88,703,000

Total revenue of $48.1M (+26% YoY); product revenue record $46.5M.
Recorlev revenue surged 86% YoY to $13.3M; Gvoke up 28% to $20.0M; Keveyis down 7% to $13.1M due to generics.
Tightens FY2024 revenue guidance to $190-200M (from $175-200M) and year-end cash to $60-75M.
John Shannon appointed CEO and Kevin McCulloch promoted to President & COO as part of succession plan.
Net loss of $15.0M ($0.10 per share); cash and equivalents $77.6M at June 30, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.